Literature DB >> 21521706

Methicillin-resistant Staphylococcus aureus: the European landscape.

Alan P Johnson1.   

Abstract

Pan-European surveillance of bacteraemia caused by methicillin-resistant Staphylococcus aureus (MRSA) shows it to be a problem affecting all European countries, although there is marked geographical variation in prevalence. Although the proportion of S. aureus bacteraemia due to MRSA is declining in many countries, data from the European Antimicrobial Resistance Surveillance System (EARSS) for 2008 showed that in more than one-third of countries the proportion remained >25%. In contrast to bacteraemia, community-associated MRSA infection in Europe remains relatively uncommon. However, there appears to be an increasing problem involving transmission of MRSA (particularly sequence type 398) from colonized livestock, particularly pigs, to farm workers, abattoir workers and veterinarians who are in contact with such animals. Molecular analysis of isolates of MRSA has shown that there has been spread of only a limited number of MRSA clones in Europe and that many of these clones show geographical clustering due to dissemination through regional healthcare networks. Despite our increasing understanding of the epidemiology of MRSA in Europe, MRSA infections continue to pose a significant public health challenge.

Entities:  

Mesh:

Year:  2011        PMID: 21521706     DOI: 10.1093/jac/dkr076

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  74 in total

1.  CMY-2-producing Escherichia coli in the nose of pigs.

Authors:  Andrea Endimiani; Markus Hilty; Vincent Perreten
Journal:  Antimicrob Agents Chemother       Date:  2012-06-05       Impact factor: 5.191

2.  Diagnostic performance of blood culture bottles for vitreous culture compared to conventional microbiological cultures in patients with suspected endophthalmitis.

Authors:  Jan Kehrmann; Valerie Chapot; Jan Buer; Philipp Rating; Norbert Bornfeld; Joerg Steinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-09       Impact factor: 3.267

3.  Methicillin-resistant Staphylococcus aureus in Zimbabwe.

Authors:  Kathrine Mauchaza; Farai D Madzimbamuto; Seymour Waner
Journal:  Ghana Med J       Date:  2016-06

4.  Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents.

Authors:  Hao Wang; Charles J Gill; Sang H Lee; Paul Mann; Paul Zuck; Timothy C Meredith; Nicholas Murgolo; Xinwei She; Susan Kales; Lianzhu Liang; Jenny Liu; Jin Wu; John Santa Maria; Jing Su; Jianping Pan; Judy Hailey; Debra Mcguinness; Christopher M Tan; Amy Flattery; Suzanne Walker; Todd Black; Terry Roemer
Journal:  Chem Biol       Date:  2013-02-21

5.  Utility of prior screening for methicillin-resistant Staphylococcus aureus in predicting resistance of S. aureus infections.

Authors:  Derek R MacFadden; Marion Elligsen; Ari Robicsek; Daniel R Ricciuto; Nick Daneman
Journal:  CMAJ       Date:  2013-09-09       Impact factor: 8.262

6.  Antibiotic prophylaxis in retrograde ureteroscopy: what strategy should we adopt?

Authors:  Cătălin Pricop; Carmen Dorobăt; Dragoş Puia; Martha Orsolya
Journal:  Germs       Date:  2013-12-01

7.  Varying fitness cost associated with resistance to fluoroquinolones governs clonal dynamic of methicillin-resistant Staphylococcus aureus.

Authors:  A Horváth; O Dobay; S Kardos; Á Ghidán; Á Tóth; J Pászti; E Ungvári; P Horváth; K Nagy; S Zissman; M Füzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-01-05       Impact factor: 3.267

Review 8.  Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.

Authors:  Nicholas A Turner; Batu K Sharma-Kuinkel; Stacey A Maskarinec; Emily M Eichenberger; Pratik P Shah; Manuela Carugati; Thomas L Holland; Vance G Fowler
Journal:  Nat Rev Microbiol       Date:  2019-04       Impact factor: 60.633

9.  Mupirocin/chlorexidine to prevent methicillin-resistant Staphylococcus aureus infections: post hoc analysis of a placebo-controlled, randomized trial using mupirocin/chlorhexidine and polymyxin/tobramycin for the prevention of acquired infections in intubated patients.

Authors:  C Camus; V Sebille; A Legras; B Garo; A Renault; P Le Corre; P-Y Donnio; A Gacouin; D Perrotin; Y Le Tulzo; E Bellissant
Journal:  Infection       Date:  2014-01-25       Impact factor: 3.553

10.  Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial.

Authors:  Michael Brandon; Michael J Dowzicky
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.